Want to see HK:6622 full AI Analyst Report?
Top Page
Zhaoke Ophthalmology Ltd.
(6622)
Select Model
Select Model
Rating:46Neutral
Price Target:
HK$2.50
▼(-21.14% Downside)
Action:Reiterated
Date:08/06/26
The score is primarily held back by weak financial performance (large losses, revenue instability, negative gross profit, and ongoing cash burn). Technical indicators add further pressure with a clear downtrend and negative momentum, while valuation is difficult to assess due to losses and lack of dividend support.
Positive Factors
Supportive balance sheet
Modest leverage and a sizable equity base provide some financial resilience while the company funds its ophthalmology pipeline. This cushion may reduce immediate balance-sheet pressure and preserve flexibility for development and commercialization, although continued losses could erode it over time.
Negative Factors
Unstable and declining revenue
The sharp revenue contraction demonstrates that commercial traction is not yet consistent and makes the current business model difficult to scale predictably. Unstable sales can constrain investment in the pipeline, weaken operating leverage, and make future funding requirements more difficult to plan.
Read all positive and negative factors
Positive Factors
Negative Factors
Supportive balance sheet
Modest leverage and a sizable equity base provide some financial resilience while the company funds its ophthalmology pipeline. This cushion may reduce immediate balance-sheet pressure and preserve flexibility for development and commercialization, although continued losses could erode it over time.
Read all positive factors
Zhaoke Ophthalmology Ltd. (6622) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.36B
Dividend YieldN/A
Average Volume (3M)179.85K
Price to Earnings (P/E)―
Beta (1Y)1.56
Revenue Growth2.56%
EPS Growth20.20%
CountryHK
Employees276
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.38
Shares Outstanding548,839,000
10 Day Avg. Volume238,550
30 Day Avg. Volume179,850
Financial Highlights & Ratios
PEG Ratio0.51
Price to Book (P/B)0.92
Price to Sales (P/S)46.69
P/FCF Ratio-5.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.32
Revenue Forecast (FY)HK$421.50M
Zhaoke Ophthalmology Ltd. Business Overview & Revenue Model
Company Description
Zhaoke Ophthalmology Limited is an ophthalmic pharmaceutical company dedicated to researching, developing, and commercializing therapeutic solutions addressing significant unmet medical requirements in the People's Republic of China. The company i...
How the Company Makes Money
null...
Zhaoke Ophthalmology Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 31.15M | 69.32M | 18.75M | 0.00 | 0.00 |
| Gross Profit | -32.57M | 51.80M | 14.25M | 0.00 | 0.00 |
| EBITDA | -215.45M | -251.23M | -327.86M | -384.55M | -377.53M |
| Net Income | -203.57M | -237.49M | -385.04M | -407.32M | -2.13B |
Balance Sheet | |||||
| Total Assets | 1.94B | 2.24B | 2.42B | 2.57B | 2.61B |
| Cash, Cash Equivalents and Short-Term Investments | 1.30B | 1.19B | 1.46B | 1.73B | 2.14B |
| Total Debt | 292.48M | 238.59M | 238.03M | 131.93M | 37.03M |
| Total Liabilities | 359.58M | 343.44M | 372.02M | 222.25M | 109.92M |
| Stockholders Equity | 1.58B | 1.90B | 2.05B | 2.35B | 2.50B |
Cash Flow | |||||
| Free Cash Flow | -265.04M | -297.79M | -418.93M | -569.60M | -339.63M |
| Operating Cash Flow | -260.20M | -253.72M | -323.66M | -331.05M | -245.14M |
| Investing Cash Flow | 109.11M | -116.45M | -75.77M | -324.57M | 683.52M |
| Financing Cash Flow | 45.63M | -12.12M | 99.29M | 76.23M | 1.66B |
Zhaoke Ophthalmology Ltd. Technical Analysis
Negative
3.17
Price Trends
2.55
Negative
2.64
Negative
2.93
Negative
Market Momentum
>-0.01
Positive
48.81
Neutral
16.41
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6622, the sentiment is Negative. The current price of 3.17 is above the 20-day moving average (MA) of 2.53, above the 50-day MA of 2.55, and above the 200-day MA of 2.93, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 48.81 is Neutral, neither overbought nor oversold. The STOCH value of 16.41 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6622.
Zhaoke Ophthalmology Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
HK:6622
Zhaoke Ophthalmology Ltd.
2.49
-1.51
-37.72%
HK:1477
Ocumension Therapeutics
5.33
-4.52
-45.89%
Zhaoke Ophthalmology Ltd. Corporate Events
Zhaoke Ophthalmology’s Presbyopia Drug YUVEZZI™ Clears Phase II Milestone in China
Sep 4, 2026
Zhaoke Ophthalmology Limited announced that its innovative presbyopia therapy, carbachol and brimonidine tartrate ophthalmic solution (YUVEZZI™), met the prespecified primary endpoint in a Phase II clinical study in Chinese patients. The mul...
Zhaoke Ophthalmology Posts Higher Revenue but Sustains Heavy R&D-Driven Losses in First Half 2026
Aug 28, 2026
Zhaoke Ophthalmology Limited reported unaudited interim results for the six months ended June 30, 2026, showing revenue of RMB18.8 million, up from RMB15.8 million a year earlier, and gross profit rising to RMB9.7 million. Despite this top-line gr...
Zhaoke Ophthalmology Sets Board Meeting to Approve Interim Results
Aug 17, 2026
Zhaoke Ophthalmology Limited has scheduled a board meeting for August 28, 2026 to review and approve the group’s unaudited interim results for the six months ended June 30, 2026. The company plans to publish these interim figures afterward, ...
Zhaoke Ophthalmology Taps Pharmentum for China Rollout of Allergy Eye Drug
Aug 12, 2026
Zhaoke Ophthalmology has signed an exclusive distribution and promotion agreement with Pharmentum Biopharma to commercialize its self-developed Epinastine Hydrochloride Eye Drops across all sales channels in mainland China. The initial term of the...
Zhaoke Ophthalmology Wins Macau Approval for Presbyopia Drug YUVEZZI
Jul 20, 2026
Zhaoke Ophthalmology has announced that its innovative presbyopia treatment YUVEZZI, a once-daily preservative-free pupil-modulating eye drop combining carbachol and brimonidine tartrate, has been approved by the Pharmaceutical Administration Bure...
Zhaoke Ophthalmology Secures Global Rights to Pediatric Myopia Drug NVK002
Jul 13, 2026
Zhaoke Ophthalmology Limited has entered into a definitive agreement to acquire the global rights to NVK002, an atropine sulfate eye drop designed to slow myopia progression in children. The deal gives Zhaoke worldwide ownership of all intellectua...
Zhaoke Ophthalmology Wins Boao Approval for First Innovative Presbyopia Drug in China
Jul 7, 2026
Zhaoke Ophthalmology’s presbyopia drug YUVEZZI, a once-daily pupil-modulating eye drop combining carbachol and brimonidine tartrate, has been approved by the Hainan Provincial Medical Products Administration for use at Boao Super Hospital as...
Zhaoke Ophthalmology’s Myopia Drug NVK002 Accepted for Australian TGA Evaluation
Jun 15, 2026
Zhaoke Ophthalmology Limited announced that Australia’s Therapeutic Goods Administration has accepted for evaluation its registration application for Atropine Sulfate Eye Drops (0.02% strength), known as NVK002, intended to slow myopia progr...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.